Wells Fargo Initiates Coverage On Bio-Rad Laboratories with Overweight Rating, Announces Price Target of $550
Portfolio Pulse from richadhand@benzinga.com
Wells Fargo analyst Dan Leonard initiates coverage on Bio-Rad Laboratories (NYSE:BIO) with an Overweight rating and a price target of $550.
June 16, 2023 | 9:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bio-Rad Laboratories receives an Overweight rating from Wells Fargo analyst Dan Leonard, with a price target of $550.
The initiation of coverage by Wells Fargo with an Overweight rating and a price target of $550 indicates a positive outlook for Bio-Rad Laboratories. This news is likely to have a positive impact on the stock price in the short term as it reflects the analyst's confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100